The purpose of this study is to determine whether MS patients who receive Oral mitoquinone
(MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's
fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if
MitoQ has a significant change in fatigue.